ArticleMethods in molecular biology (Clifton, N.J.)2020
Development of a Mouse-Adapted MERS Coronavirus.
Article in Methods in molecular biology (Clifton, N.J.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 20 citations in OpenAlex.
- High genomic stability of Andes virus following successive passageJournal of virology · 2025Article
- Article
- Sex bias determines MERS-CoV infection outcomes in a mouse model of differential pathogenicity.bioRxiv : the preprint server for biology · 2025Article
- Review
- Article
- Boosting the anti MERS-CoV activity and oral bioavailability of resveratrol via PEG-stabilized emulsomal nano-carrier: Factorial design, in-vitro and in-vivo assessments.Drug delivery · 2022Article
- Article
- Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19.Frontiers in immunology · 2022Article
- A Mouse Model of Ulcerative Cutaneous Leishmaniasis byFrontiers in microbiology · 2022Article
- Article
- Mouse Models for the Study of SARS-CoV-2 Infection.Comparative medicine · 2021Review
- Inter-individual Variation in Receptor Expression Influences MERS-CoV Infection and Immune Responses in Airway Epithelia.Frontiers in public health · 2021Article
- SARS-CoV-2 in animals: From potential hosts to animal models.Advances in virus research · 2021Article
- Sex-dependent immune response and lethality of COVID-19.Stem cell research · 2021Article
- Selection of animal models for COVID-19 research.Virusdisease · 2020Article
- Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy.Science (New York, N.Y.) · 2020Article
- SARS-CoV-2 neutralizing antibody development strategies.Turkish journal of biology = Turk biyoloji dergisi · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
First identified in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel virus that can cause acute respiratory distress syndrome (ARDS), multiorgan failure, and death, with a case fatality rate of ~35%. An animal model that supports MERS-CoV infection and causes severe lung disease is useful to study pathogenesis and evaluate therapies and vaccines. The murine dipeptidyl peptidase 4 (Dpp4) protein is not a functional receptor for MERS-CoV; thus, mice are resistant to MERS-CoV infection. We generated human DPP4 knock-in (hDPP4 KI) mice by replacing exons 10-12 at the mouse Dpp4 locus with exons 10-12 from the human DPP4 gene. The resultant human DPP4 KI mice are permissive to MERS-CoV (HCoV-EMC/2012 strain) infection but develop no disease. To generate a mouse model with associated morbidity and mortality from respiratory disease, we serially passaged HCoV-EMC/2012 strain in the lungs of young hDPP4 KI mice. After 30 in vivo passages, an adapted virus clone was isolated and designated MERS
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.